Please login to the form below

Not currently logged in
Email:
Password:

WuXi PharmaTech hires for three senior level positions

WuXi PharmaTech hires new staff to three key senior level positions, including executive vice-president of operations, vice-president of toxicology and vice-president of finance

WuXi PharmaTech, a Chinese-headquartered provider of pharmaceutical R&D outsourcing services, has made hires to three key senior level positions, including executive vice-president of operations, vice-president of toxicology and vice-president of finance.

Mr Edward Hu will serve as WuXi PharmaTech's executive vice-president of operations, and will report directly to Dr Ge Li, who is WuXi's chairman and CEO. Hu brings an extensive experience in operations and financial management. Before his appointment with WuXi PharmaTech, he was the senior vice-president and COO of Tanox, where he managed operations, finance, IT, project management and strategic planning. Hu has also held management positions at Biogen Idec and Merck.

Dr Victor H Chen will serve as vice-president and head of toxicology at SuZhou PharmaTech and will report directly to Dr Ge Li, chairman and CEO of the company.

Chen will work closely with Dr Lijie Fu, head of operations at SuZhou PharmaTech to further enhance WuXi's capability and capacity in Toxicology services.

Prior to joining WuXi PharmaTech, Dr. Chen held the position of director of toxicology for ImClone Systems. He has previously held positions at Pfizer and Bristol-Myers Squibb, as well as at the University of Hawaii.

Reporting to Mr Benson Tsang, WuXI's CFO, Christine Lu-Wong has been appointed as vice-president of finance. Lu-Wong has held various finance positions at multi-national companies, such as Hewlett-Packard and Sun Microsystems. Prior to joining WuXi PharmaTech, Lu-Wong consulted many companies in San Jose, California including Google and Altera.

14th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics